Baudax Bio, Inc.
Baudax Bio, Inc., a biopharmaceutical company headquartered in the United States, focuses on developing innovative therapeutics for patients in need. Founded in 2018, Baudax Bio has quickly established itself in the industry, particularly in the areas of pain management and anaesthesia. The company’s flagship product, Exparel, is a unique liposomal formulation of bupivacaine, designed to provide prolonged analgesia with a single administration. This innovative approach sets Baudax Bio apart in a competitive market, addressing the growing demand for effective pain relief solutions. With a commitment to advancing patient care, Baudax Bio has achieved significant milestones, positioning itself as a key player in the biopharmaceutical landscape. The company continues to explore new avenues for growth, aiming to enhance the quality of life for patients worldwide.
DitchCarbon Score
How does Baudax Bio, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Baudax Bio, Inc.'s score of 23 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Baudax Bio, Inc.'s reported carbon emissions
Baudax Bio, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi) or other industry standards. As there is no available data on emissions or reduction initiatives, Baudax Bio's climate commitments remain unclear. The company may need to develop and communicate its sustainability strategies to align with industry practices and expectations regarding carbon emissions and climate action.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Baudax Bio, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
